Irf1M1Btlr/Irf1+
C57BL/6J-Irf1M1Btlr
|
decreased CD8-positive, alpha-beta T cell number |
J:162995
|
decreased NK cell number |
J:162995
|
normal
hematopoietic system phenotype |
J:162995
|
normal
immune system phenotype |
J:162995
|
impaired natural killer cell mediated cytotoxicity |
J:162995
|
increased susceptibility to Herpesvirales infection |
J:162995
|
Irf1M1Btlr/Irf1M1Btlr
C57BL/6J-Irf1M1Btlr
|
decreased CD8-positive, alpha-beta T cell number |
J:162995
|
decreased interferon-alpha secretion |
J:162995
|
decreased interferon-beta secretion |
J:162995
|
decreased NK cell number |
J:162995
|
normal
hematopoietic system phenotype |
J:162995
|
normal
immune system phenotype |
J:162995
|
impaired natural killer cell mediated cytotoxicity |
J:162995
|
increased susceptibility to Herpesvirales infection |
J:162995
|
Irf1m2Btlr/Irf1m2Btlr
C57BL/6J-Irf1m2Btlr
|
decreased CD8-positive, alpha-beta T cell number |
J:267675
|
decreased NK cell number |
J:267675
|
increased B-1 B cell number |
J:267675
|
increased CD4-positive, alpha-beta T cell number |
J:267675
|
Irf1M3Btlr/Irf1M3Btlr
C57BL/6J-Irf1M3Btlr
|
decreased CD8-positive, alpha-beta T cell number |
J:267677
|
increased CD4-positive, alpha-beta T cell number |
J:267677
|
Irf1tm1Cwe/Irf1tm1Cwe
involves: 129
|
abnormal circulating interleukin-4 level |
J:84367
|
abnormal circulating interleukin-10 level |
J:84367
|
abnormal cytokine level |
J:84367
|
abnormal T cell proliferation |
J:84367
|
decreased circulating interferon-gamma level |
J:84367
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:84367
|
increased circulating interleukin-5 level |
J:84367
|
increased circulating interleukin-6 level |
J:84367
|
increased circulating interleukin-13 level |
J:84367
|
Irf1tm1Cwe/Irf1tm1Cwe
involves: 129/Sv * C57BL/6
|
abnormal cytokine level |
J:110672
|
abnormal immune system morphology |
J:21235
|
abnormal immune system physiology |
J:43086
|
abnormal immunoglobulin level |
J:101427
|
abnormal macrophage physiology |
J:43086
|
abnormal splenocyte morphology |
J:21235
|
abnormal T cell morphology |
J:21235,
J:36025
|
abnormal thymus cell ratio |
J:36025
|
decreased CD8-positive, alpha-beta T cell number |
J:21235
|
decreased circulating interleukin-2 level |
J:110672
|
decreased susceptibility to induced arthritis |
J:43086
|
increased circulating interferon-gamma level |
J:110672
|
increased circulating interleukin-3 level |
J:110672
|
increased circulating interleukin-4 level |
J:110672
|
increased circulating interleukin-5 level |
J:110672
|
increased circulating interleukin-6 level |
J:110672
|
increased susceptibility to Poxviridae infection |
J:101427
|
increased T-helper 2 cell number |
J:110672
|
normal
skeleton phenotype |
J:43086
|
Irf1tm1Mak/Irf1+
either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)
|
no abnormal phenotype detected |
J:64286
|
Irf1tm1Mak/Irf1tm1Mak
B6.129S2-Irf1tm1Mak/J
|
abnormal circulating alanine transaminase level |
J:111090
|
abnormal lymphocyte physiology |
J:91927
|
decreased interferon-gamma secretion |
J:91927
|
increased incidence of tumors by chemical induction |
J:91927
|
increased lymphoma incidence |
J:91927
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:91927
|
Irf1tm1Mak/Irf1tm1Mak
either: (involves: 129S2/SvPas * C57BL/6J) or (involves: 129S2/SvPas * C57BL/6J * DBA/2)
|
abnormal response to infection |
J:64286
|
abnormal T cell number |
J:64286
|
decreased CD8-positive, alpha-beta T cell number |
J:64286
|
normal
immune system phenotype |
J:64286
|
increased CD4-positive, alpha-beta T cell number |
J:64286
|
increased double-positive T cell number |
J:64286
|
Irf1tm1Mak/Irf1tm1Mak
involves: 129S2/SvPas
|
abnormal DNA repair |
J:115104
|
normal
cellular phenotype |
J:115104
|
Irf1tm1Mak/Irf1tm1Mak
involves: 129S2/SvPas * C57BL/6J
|
abnormal vascular wound healing |
J:118512
|